aluates Reports

$ 0.0

Automative

Global Nanomaterial-Based Adjuvants Vaccine Market Research Report 2024

Published Date: March 2024

Report Code: QYRE-Auto-4M9386

Global Nanomaterial Based Adjuvants Vaccine Market Insights and Forecast to 2028

BUY CHAPTERS

Global Nanomaterial-Based Adjuvants Vaccine Market Research Report 2024

Code: QYRE-Auto-4M9386

Report

March 2024

Pages:82

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

GlaxoSmithKline Biologicals

Merck

Pfizer Inc

Novartis

Moderna, Inc

Emergent Biosolutions

Sanofi

Nanomaterial-Based Adjuvants Vaccine Market Size

The global Nanomaterial-Based Adjuvants Vaccine market was valued at US$ 59090 million in 2023 and is anticipated to reach US$ 40890 million by 2030, witnessing a CAGR of 8.0% during the forecast period 2024-2030.

Nanomaterial-Based Adjuvants Vaccine Market

Global key players of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, etc. Global top 3 companies hold a share over 80%. North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%. In terms of product, Lipidosome is the largest segment, with a share about 80%. And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

This report aims to provide a comprehensive presentation of the global market for Nanomaterial-Based Adjuvants Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanomaterial-Based Adjuvants Vaccine.

Report Scope

The Nanomaterial-Based Adjuvants Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Nanomaterial-Based Adjuvants Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Nanomaterial-Based Adjuvants Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Nanomaterial-Based Adjuvants Vaccine Market Report

Report Metric	Details
Report Name	Nanomaterial-Based Adjuvants Vaccine Market
Accounted market size in 2023	US$ 59090 million
Forecasted market size in 2030	US$ 40890 million
CAGR	8.0%
Base Year	2023
Forecasted years	2024 - 2030
Segment by Type	Aluminium Hydroxides Aluminium Phosphate Lipidosome Others
Segment by Application	Pneumococcus Human Papilloma Virus DTaP Viral Hepatitis TypeA Viral Hepatitis TypeB SARS-CoV-2 Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Nanomaterial-Based Adjuvants Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Nanomaterial-Based Adjuvants Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Nanomaterial-Based Adjuvants Vaccine Market growing?

Ans: The Nanomaterial-Based Adjuvants Vaccine Market witnessing a CAGR of 8.0% during the forecast period 2024-2030.

What is the Nanomaterial-Based Adjuvants Vaccine Market size in 2030?

Ans: The Nanomaterial-Based Adjuvants Vaccine Market size in 2030 will be US$ 40890 million.

What is the market share of major companies in Nanomaterial-Based Adjuvants Vaccine Market?

Ans: Global top 3 companies hold a share over 80%.

What is the Nanomaterial-Based Adjuvants Vaccine Market share by region?

Ans: North America is the largest market, with a share about 60%, followed by Europe and Japan with the share about 20% and 5%.

What is the Nanomaterial-Based Adjuvants Vaccine Market share by type?

Ans: In terms of product, Lipidosome is the largest segment, with a share about 80%.

What is the Nanomaterial-Based Adjuvants Vaccine Market share by application?

Ans: And in terms of application, the largest application is SARS-CoV-2, with a share about 75%.

Who are the main players in the Nanomaterial-Based Adjuvants Vaccine Market report?

Ans: The main players in the Nanomaterial-Based Adjuvants Vaccine Market are Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis, Moderna

What are the Application segmentation covered in the Nanomaterial-Based Adjuvants Vaccine Market report?

Ans: The Applications covered in the Nanomaterial-Based Adjuvants Vaccine Market report are Pneumococcus, Human Papilloma Virus, DTaP, Viral Hepatitis TypeA, Viral Hepatitis TypeB, SARS-CoV-2, Others

What are the Type segmentation covered in the Nanomaterial-Based Adjuvants Vaccine Market report?

Ans: The Types covered in the Nanomaterial-Based Adjuvants Vaccine Market report are Aluminium Hydroxides, Aluminium Phosphate, Lipidosome, Others

1 Nanomaterial-Based Adjuvants Vaccine Market Overview

1.1 Product Overview and Scope of Nanomaterial-Based Adjuvants Vaccine

1.2 Nanomaterial-Based Adjuvants Vaccine Segment by Type

1.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Type (2024-2030)

1.2.2 Aluminium Hydroxides

1.2.3 Aluminium Phosphate

1.2.4 Lipidosome

1.2.5 Others

1.3 Nanomaterial-Based Adjuvants Vaccine Segment by Application

1.3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Value by Application: (2024-2030)

1.3.2 Pneumococcus

1.3.3 Human Papilloma Virus

1.3.4 DTaP

1.3.5 Viral Hepatitis TypeA

1.3.6 Viral Hepatitis TypeB

1.3.7 SARS-CoV-2

1.3.8 Others

1.4 Global Nanomaterial-Based Adjuvants Vaccine Market Size Estimates and Forecasts

1.4.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue 2019-2030

1.4.2 Global Nanomaterial-Based Adjuvants Vaccine Sales 2019-2030

1.4.3 Global Nanomaterial-Based Adjuvants Vaccine Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Nanomaterial-Based Adjuvants Vaccine Market Competition by Manufacturers

2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2019-2024)

2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Nanomaterial-Based Adjuvants Vaccine Average Price by Manufacturers (2019-2024)

2.4 Global Nanomaterial-Based Adjuvants Vaccine Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Type & Application

2.7 Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation and Trends

2.7.1 Nanomaterial-Based Adjuvants Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue

2.7.3 Global Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Nanomaterial-Based Adjuvants Vaccine Retrospective Market Scenario by Region

3.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Nanomaterial-Based Adjuvants Vaccine Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2019-2030

3.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2019-2024

3.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2025-2030

3.3 Global Nanomaterial-Based Adjuvants Vaccine Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2019-2030

3.3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2019-2024

3.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2025-2030

3.4 North America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country

3.4.1 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2030)

3.4.3 North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country

3.5.1 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2030)

3.5.3 Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2030)

3.6.3 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country

3.7.1 Latin America Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2030)

3.7.3 Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2030)

3.8.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2019-2030)

4.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2019-2024)

4.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2025-2030)

4.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2019-2030)

4.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2019-2030)

4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2019-2024)

4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2025-2030)

4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2019-2030)

4.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Type (2019-2030)

5 Segment by Application

5.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2019-2030)

5.1.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2019-2024)

5.1.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2025-2030)

5.1.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2019-2030)

5.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2019-2030)

5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2019-2024)

5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2025-2030)

5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2019-2030)

5.3 Global Nanomaterial-Based Adjuvants Vaccine Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Emergent BioSolutions

6.1.1 Emergent BioSolutions Corporation Information

6.1.2 Emergent BioSolutions Description and Business Overview

6.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.1.5 Emergent BioSolutions Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Corporation Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 GlaxoSmithKline Biologicals

6.3.1 GlaxoSmithKline Biologicals Corporation Information

6.3.2 GlaxoSmithKline Biologicals Description and Business Overview

6.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.3.5 GlaxoSmithKline Biologicals Recent Developments/Updates

6.4 Merck

6.4.1 Merck Corporation Information

6.4.2 Merck Description and Business Overview

6.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.4.5 Merck Recent Developments/Updates

6.5 Pfizer

6.5.1 Pfizer Corporation Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

6.6 Novartis

6.6.1 Novartis Corporation Information

6.6.2 Novartis Description and Business Overview

6.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.6.5 Novartis Recent Developments/Updates

6.7 Moderna

6.6.1 Moderna Corporation Information

6.6.2 Moderna Description and Business Overview

6.6.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio

6.7.5 Moderna Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Nanomaterial-Based Adjuvants Vaccine Industry Chain Analysis

7.2 Nanomaterial-Based Adjuvants Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process

7.4 Nanomaterial-Based Adjuvants Vaccine Sales and Marketing

7.4.1 Nanomaterial-Based Adjuvants Vaccine Sales Channels

7.4.2 Nanomaterial-Based Adjuvants Vaccine Distributors

7.5 Nanomaterial-Based Adjuvants Vaccine Customers

8 Nanomaterial-Based Adjuvants Vaccine Market Dynamics

8.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends

8.2 Nanomaterial-Based Adjuvants Vaccine Market Drivers

8.3 Nanomaterial-Based Adjuvants Vaccine Market Challenges

8.4 Nanomaterial-Based Adjuvants Vaccine Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

GlaxoSmithKline Biologicals

Merck

Pfizer Inc

Novartis

Moderna, Inc

Emergent Biosolutions

Sanofi

List of Tables

Table 1. Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Nanomaterial-Based Adjuvants Vaccine Market Competitive Situation by Manufacturers in 2023

Table 4. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) of Key Manufacturers (2019-2024)

Table 5. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Nanomaterial-Based Adjuvants Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Nanomaterial-Based Adjuvants Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Nanomaterial-Based Adjuvants Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nanomaterial-Based Adjuvants Vaccine as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2019-2024) & (M Doses)

Table 18. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2019-2024)

Table 19. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2025-2030) & (M Doses)

Table 20. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2025-2030)

Table 21. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2019-2024)

Table 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2025-2030)

Table 25. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2024) & (M Doses)

Table 27. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2025-2030) & (M Doses)

Table 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2024) & (M Doses)

Table 32. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2025-2030) & (M Doses)

Table 33. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2019-2024) & (M Doses)

Table 37. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Region (2025-2030) & (M Doses)

Table 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2024) & (M Doses)

Table 42. Latin America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2025-2030) & (M Doses)

Table 43. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2019-2024) & (M Doses)

Table 47. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2025-2030) & (M Doses)

Table 48. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2019-2024)

Table 51. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Type (2025-2030)

Table 52. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2019-2024)

Table 53. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2025-2030)

Table 54. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2019-2024)

Table 57. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2025-2030)

Table 58. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2019-2024)

Table 59. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2025-2030)

Table 60. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2019-2024)

Table 61. Global Nanomaterial-Based Adjuvants Vaccine Sales (M Doses) by Application (2025-2030)

Table 62. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2019-2024)

Table 63. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2025-2030)

Table 64. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Nanomaterial-Based Adjuvants Vaccine Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2019-2024)

Table 67. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2025-2030)

Table 68. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2019-2024)

Table 69. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2025-2030)

Table 70. Emergent BioSolutions Corporation Information

Table 71. Emergent BioSolutions Description and Business Overview

Table 72. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 73. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product

Table 74. Emergent BioSolutions Recent Developments/Updates

Table 75. Sanofi Corporation Information

Table 76. Sanofi Description and Business Overview

Table 77. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 78. Sanofi Nanomaterial-Based Adjuvants Vaccine Product

Table 79. Sanofi Recent Developments/Updates

Table 80. GlaxoSmithKline Biologicals Corporation Information

Table 81. GlaxoSmithKline Biologicals Description and Business Overview

Table 82. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 83. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product

Table 84. GlaxoSmithKline Biologicals Recent Developments/Updates

Table 85. Merck Corporation Information

Table 86. Merck Description and Business Overview

Table 87. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 88. Merck Nanomaterial-Based Adjuvants Vaccine Product

Table 89. Merck Recent Developments/Updates

Table 90. Pfizer Corporation Information

Table 91. Pfizer Description and Business Overview

Table 92. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 93. Pfizer Nanomaterial-Based Adjuvants Vaccine Product

Table 94. Pfizer Recent Developments/Updates

Table 95. Novartis Corporation Information

Table 96. Novartis Description and Business Overview

Table 97. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 98. Novartis Nanomaterial-Based Adjuvants Vaccine Product

Table 99. Novartis Recent Developments/Updates

Table 100. Moderna Corporation Information

Table 101. Moderna Description and Business Overview

Table 102. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)

Table 103. Moderna Nanomaterial-Based Adjuvants Vaccine Product

Table 104. Moderna Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Nanomaterial-Based Adjuvants Vaccine Distributors List

Table 108. Nanomaterial-Based Adjuvants Vaccine Customers List

Table 109. Nanomaterial-Based Adjuvants Vaccine Market Trends

Table 110. Nanomaterial-Based Adjuvants Vaccine Market Drivers

Table 111. Nanomaterial-Based Adjuvants Vaccine Market Challenges

Table 112. Nanomaterial-Based Adjuvants Vaccine Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Nanomaterial-Based Adjuvants Vaccine

Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Type in 2023 & 2030

Figure 4. Aluminium Hydroxides Product Picture

Figure 5. Aluminium Phosphate Product Picture

Figure 6. Lipidosome Product Picture

Figure 7. Others Product Picture

Figure 8. Global Nanomaterial-Based Adjuvants Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 9. Global Nanomaterial-Based Adjuvants Vaccine Market Share by Application in 2023 & 2030

Figure 10. Pneumococcus

Figure 11. Human Papilloma Virus

Figure 12. DTaP

Figure 13. Viral Hepatitis TypeA

Figure 14. Viral Hepatitis TypeB

Figure 15. SARS-CoV-2

Figure 16. Others

Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Nanomaterial-Based Adjuvants Vaccine Market Size (2019-2030) & (US$ Million)

Figure 19. Global Nanomaterial-Based Adjuvants Vaccine Sales (2019-2030) & (M Doses)

Figure 20. Global Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Dose) & (2019-2030)

Figure 21. Nanomaterial-Based Adjuvants Vaccine Report Years Considered

Figure 22. Nanomaterial-Based Adjuvants Vaccine Sales Share by Manufacturers in 2023

Figure 23. Global Nanomaterial-Based Adjuvants Vaccine Revenue Share by Manufacturers in 2023

Figure 24. The Global 5 and 10 Largest Nanomaterial-Based Adjuvants Vaccine Players: Market Share by Revenue in 2023

Figure 25. Nanomaterial-Based Adjuvants Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 27. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2019-2030)

Figure 28. North America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2019-2030)

Figure 29. United States Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Canada Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2019-2030)

Figure 32. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2019-2030)

Figure 33. Germany Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. France Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. U.K. Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Italy Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Russia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2019-2030)

Figure 39. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2019-2030)

Figure 40. China Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. Japan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. South Korea Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. India Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Australia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. China Taiwan Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Indonesia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Thailand Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Malaysia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Latin America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2019-2030)

Figure 50. Latin America Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2019-2030)

Figure 51. Mexico Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Brazil Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Argentina Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2019-2030)

Figure 55. Middle East & Africa Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Country (2019-2030)

Figure 56. Turkey Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 57. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. UAE Nanomaterial-Based Adjuvants Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 59. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2019-2030)

Figure 60. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Type (2019-2030)

Figure 61. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Type (2019-2030)

Figure 62. Global Sales Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2019-2030)

Figure 63. Global Revenue Market Share of Nanomaterial-Based Adjuvants Vaccine by Application (2019-2030)

Figure 64. Global Nanomaterial-Based Adjuvants Vaccine Price (US$/Dose) by Application (2019-2030)

Figure 65. Nanomaterial-Based Adjuvants Vaccine Value Chain

Figure 66. Nanomaterial-Based Adjuvants Vaccine Production Process

Figure 67. Channels of Distribution (Direct Vs Distribution)

Figure 68. Distributors Profiles

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions